Iovance Biotherapeutics (IOVA) AI Stock Analysis

• Market Cap: $712.85M
• Dividend Yield: N/A
• Average Volume (3M): 21.99M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.16
• Revenue Growth: 636.99%
• EPS Growth: 27.10%
• Country: US
• Employees: 838
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): -0.33
• Shares Outstanding: 361,853,880
• 10 Day Avg. Volume: 18,456,294
• 30 Day Avg. Volume: 21,994,143
• PEG Ratio: 0.18
• Price to Book (P/B): 3.02
• Price to Sales (P/S): 13.07
• P/FCF Ratio: -5.89
• Enterprise Value/Market Cap: 0.46
• Enterprise Value/Revenue: 1.54
• Enterprise Value/Gross Profit: 8.02
• Enterprise Value/Ebitda: -0.92
• 1Y Price Target: $6.86
• Price Target Upside: 207.62% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 9

• Rating: 51 Neutral
• Price Target: $2.00 ▼(-10.31% Downside)

Iovance Biotherapeutics shows strong revenue growth and strategic initiatives for cost savings, which are positive indicators. However, ongoing unprofitability, negative cash flow, and valuation concerns weigh heavily on the stock's overall score. The technical indicators suggest a bearish trend, and recent corporate changes add some uncertainty.

Positive Factors

Regulatory Approvals

AMTAGVI is on track for approval or regulatory submission in four ex-U.S. markets, including Canada, U.K., Australia, and Switzerland, which are significant commercial opportunities.

Strategic Restructuring

Iovance is entering a strategic restructuring estimated to save approximately $100 million annually, reduce cash burn, and improve gross margins without significant changes to the clinical pipeline.

Negative Factors

Regulatory Challenges

IOVA withdrew its application to the EMA following lack of alignment during discussions on clinical data.

Revenue Performance

The stock was down approximately 35% in after-hours trading due to lackluster revenue and a lack of concrete catalysts or milestones in the near term.

Iovance Biotherapeutics Business Overview & Revenue Model

Company Description

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

How the Company Makes Money

Iovance Biotherapeutics generates revenue primarily through the development and commercialization of its cell therapy products. The company may earn revenue from product sales once its therapies receive regulatory approval and enter the market. Additionally, Iovance may engage in strategic partnerships and collaborations with larger pharmaceutical companies, which can provide upfront payments, milestone payments upon achieving specific development goals, and royalties on future sales of the therapies developed under these agreements. These partnerships not only enhance Iovance's financial resources but also facilitate the advancement of its product candidates through clinical trials and regulatory processes. Research grants and funding from government or non-profit organizations may also contribute to the company's revenue streams, particularly during the development stages of its therapies.

Iovance Biotherapeutics Financial Statement Overview

Summary

Iovance Biotherapeutics is experiencing significant revenue growth, marking its first substantial revenue generation. However, the company remains unprofitable with a negative net income and negative cash flow, indicating operational and profitability challenges. The balance sheet shows a strong equity position with low leverage, but sustained losses could impact financial stability.

Income Statement

Iovance Biotherapeutics has shown substantial revenue growth with total revenue increasing significantly from $1.18 million in 2023 to $212.68 million in TTM (Trailing-Twelve-Months), marking its first substantial revenue generation. However, despite revenue growth, the company remains unprofitable with a negative net income of $375.36 million in TTM. The gross profit margin is 19.2% in TTM, reflecting that costs are still high relative to revenue. The EBIT and EBITDA margins are negative, indicating ongoing operational inefficiencies and high operating costs.

Balance Sheet

The balance sheet shows a relatively strong equity position, with a debt-to-equity ratio of 0.07, suggesting low leverage. Stockholders' equity stands at $767.87 million, indicating financial stability. However, the negative net income affects the return on equity, which remains negative. The equity ratio is 79.4%, reflecting a strong capital structure with substantial equity financing.

Cash Flow

The company has a negative operating cash flow of $334.39 million in TTM, demonstrating cash outflows from operations. Free cash flow also remains negative at $347.50 million, indicating challenges in generating cash from operations after capital expenditures. However, the firm successfully raised $340.40 million through financing activities, supporting its cash position.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	212.68M	164.07M	1.19M	0.00	0.00	0.00
Gross Profit	40.83M	40.08M	-9.57M	-21.14M	-13.98M	-8.71M
EBITDA	-354.01M	-351.67M	-427.43M	-374.76M	-328.27M	-250.87M
Net Income	-375.36M	-372.18M	-444.04M	-395.89M	-342.25M	-259.58M
Balance Sheet
Total Assets	966.74M	910.43M	780.35M	663.98M	777.33M	768.46M
Cash, Cash Equivalents and Short-Term Investments	359.71M	323.78M	279.87M	471.85M	504.41M	629.44M
Total Debt	53.72M	58.26M	75.86M	85.45M	71.53M	51.66M
Total Liabilities	198.88M	200.02M	195.74M	164.34M	155.67M	111.96M
Stockholders Equity	767.87M	710.40M	584.61M	499.64M	621.66M	656.50M
Cash Flow
Free Cash Flow	-347.50M	-364.05M	-384.11M	-313.18M	-265.51M	-251.93M
Operating Cash Flow	-334.39M	-352.98M	-361.82M	-292.76M	-227.94M	-205.13M
Investing Cash Flow	30.96M	-96.41M	-155.24M	256.45M	132.00K	-317.85M
Financing Cash Flow	340.40M	390.66M	462.96M	190.15M	239.27M	576.42M

Iovance Biotherapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.23
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IOVA, the sentiment is Negative. The current price of 2.23 is below the 20-day moving average (MA) of 2.69, below the 50-day MA of 2.23, and below the 200-day MA of 4.86, indicating a bearish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 45.66 is Neutral, neither overbought nor oversold. The STOCH value of 19.03 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IOVA.

Iovance Biotherapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	60 Neutral	HK$18.14B	4.94	-4.00%	3.36%	10.19%	-23.62%
IMTX	57 Neutral	$770.63M	53.85	-4.52%	―	92.31%	78.17%
AMLX	56 Neutral	$697.29M	―	-87.42%	―	-100.08%	-2.45%
IOVA	51 Neutral	$712.85M	―	-53.16%	―	636.99%	27.10%
VIR	48 Neutral	$594.56M	―	-46.22%	―	-75.91%	-12.11%
KALV	45 Neutral	$611.93M	―	-121.50%	―	―	-10.46%
NUVB	45 Neutral	$768.93M	―	-64.40%	―	900.35%	70.25%

Iovance Biotherapeutics Corporate Events

Iovance Biotherapeutics Reports Q2 2025 Financial Results

Iovance Biotherapeutics reported its financial results for the second quarter and first half of 2025, highlighting a total product revenue of $60 million in Q2, driven by the U.S. sales of Amtagvi and Proleukin. The company is expanding its market reach with regulatory approvals expected in Canada and other countries, and it continues to advance its TIL cell therapy pipeline with ongoing clinical trials and strategic restructuring to extend its cash runway into the fourth quarter of 2026.

The most recent analyst rating on (IOVA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Iovance Biotherapeutics stock, see the IOVA Stock Forecast page.

Iovance Biotherapeutics Appoints New Chief Financial Officer

On July 15, 2025, Iovance Biotherapeutics announced the appointment of Corleen Roche as Chief Financial Officer, effective August 6, 2025. Ms. Roche, who brings over 30 years of experience in the biotech and life sciences industry, will replace Matthew W. Rosinack. Her extensive background in executive financial leadership and product launches is expected to be invaluable as Iovance focuses on revenue growth and advancing its mission of developing novel therapies for cancer patients. This strategic appointment is seen as a significant step for Iovance as it navigates its first commercial launch and aims to strengthen its position in the biotechnology industry.

The most recent analyst rating on (IOVA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Iovance Biotherapeutics stock, see the IOVA Stock Forecast page.

Iovance Biotherapeutics CFO Resignation and Interim Appointment

On June 30, 2025, Iovance Biotherapeutics announced the resignation of Jean-Marc Bellemin as Chief Financial Officer, effective immediately, with Matthew W. Rosinack stepping in as interim Principal Financial Officer and Principal Accounting Officer. Rosinack, who has extensive experience in finance roles at various biotechnology and medical device companies, has been with Iovance since September 2021 and will temporarily fill the role as the company navigates this transition.

The most recent analyst rating on (IOVA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Iovance Biotherapeutics stock, see the IOVA Stock Forecast page.

Iovance Biotherapeutics CFO Resignation Announced

On June 10, 2025, Jean-Marc Bellemin, the Chief Financial Officer of Iovance Biotherapeutics, announced his resignation effective July 10, 2025, to pursue other opportunities. This departure may impact the company’s financial leadership and strategic direction as it continues to develop cancer immunotherapies.

The most recent analyst rating on (IOVA) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Iovance Biotherapeutics stock, see the IOVA Stock Forecast page.

Iovance Biotherapeutics Approves Key Proposals at Annual Meeting

On June 10, 2025, Iovance Biotherapeutics held its Annual Meeting of Stockholders virtually, where stockholders voted on five key proposals. These included the election of directors, approval of executive compensation, ratification of Ernst & Young LLP as the accounting firm, and amendments to increase shares in the equity incentive and employee stock purchase plans. All proposals were approved, reflecting strong shareholder support and potentially enhancing the company’s operational flexibility and strategic initiatives.

The most recent analyst rating on (IOVA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Iovance Biotherapeutics stock, see the IOVA Stock Forecast page.